JP2015512612A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512612A5
JP2015512612A5 JP2014552348A JP2014552348A JP2015512612A5 JP 2015512612 A5 JP2015512612 A5 JP 2015512612A5 JP 2014552348 A JP2014552348 A JP 2014552348A JP 2014552348 A JP2014552348 A JP 2014552348A JP 2015512612 A5 JP2015512612 A5 JP 2015512612A5
Authority
JP
Japan
Prior art keywords
patient
expression
gene
level
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552348A
Other languages
English (en)
Japanese (ja)
Other versions
JP6529261B2 (ja
JP2015512612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021306 external-priority patent/WO2013106765A1/en
Publication of JP2015512612A publication Critical patent/JP2015512612A/ja
Publication of JP2015512612A5 publication Critical patent/JP2015512612A5/ja
Application granted granted Critical
Publication of JP6529261B2 publication Critical patent/JP6529261B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552348A 2012-01-13 2013-01-11 Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー Expired - Fee Related JP6529261B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586660P 2012-01-13 2012-01-13
US61/586,660 2012-01-13
PCT/US2013/021306 WO2013106765A1 (en) 2012-01-13 2013-01-11 Biological markers for identifying patients for treatment with vegf antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017237944A Division JP2018082705A (ja) 2012-01-13 2017-12-12 Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー

Publications (3)

Publication Number Publication Date
JP2015512612A JP2015512612A (ja) 2015-04-30
JP2015512612A5 true JP2015512612A5 (https=) 2016-03-03
JP6529261B2 JP6529261B2 (ja) 2019-06-12

Family

ID=48781962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014552348A Expired - Fee Related JP6529261B2 (ja) 2012-01-13 2013-01-11 Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー
JP2017237944A Pending JP2018082705A (ja) 2012-01-13 2017-12-12 Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017237944A Pending JP2018082705A (ja) 2012-01-13 2017-12-12 Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー

Country Status (16)

Country Link
US (2) US10364466B2 (https=)
EP (1) EP2802346B1 (https=)
JP (2) JP6529261B2 (https=)
KR (1) KR20140114415A (https=)
CN (1) CN104203268A (https=)
AU (2) AU2013207778B2 (https=)
BR (1) BR112014017320A2 (https=)
CA (1) CA2862835A1 (https=)
HK (1) HK1204933A1 (https=)
IL (2) IL233467B (https=)
MX (1) MX356802B (https=)
NZ (1) NZ627443A (https=)
RU (1) RU2659173C2 (https=)
SG (1) SG11201403927XA (https=)
WO (1) WO2013106765A1 (https=)
ZA (1) ZA201405305B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
SG11201504023SA (en) 2012-12-03 2015-06-29 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
US10456470B2 (en) * 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US10941446B2 (en) 2014-03-12 2021-03-09 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
DK3134119T3 (en) 2014-04-24 2018-10-22 Pfizer CANCER TREATMENT
GB201409478D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Pro-angiogenic signature
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
CN113444783B (zh) 2014-06-26 2024-04-09 西奈山伊坎医学院 通过分析预示性基因集诊断亚临床和临床的急性排异的方法
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CA2963091A1 (en) * 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016118670A1 (en) * 2015-01-20 2016-07-28 Memorial Sloan-Kettering Cancer Center Multigene expression assay for patient stratification in resected colorectal liver metastases
EP3067698A1 (en) * 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
WO2017096031A1 (en) * 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
US9845505B2 (en) 2016-01-29 2017-12-19 BluePrint Bio, Inc. Prediction of therapeutic response in inflammatory conditions
MX2018012493A (es) * 2016-04-15 2019-06-06 Genentech Inc Métodos para controlar y tratar el cáncer.
KR20180134347A (ko) * 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
EP3523779B1 (en) * 2016-10-07 2026-04-29 Ventana Medical Systems, Inc. Digital pathology system and associated workflow for providing visualized whole-slide image analysis
EP3550305A4 (en) * 2016-12-01 2020-11-11 Santen Pharmaceutical Co., Ltd. METHOD OF PREDICTING THE EFFECTIVENESS OF AN ANTI-VEGF ACTIVE INGREDIENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
TW201837467A (zh) 2017-03-01 2018-10-16 美商建南德克公司 用於癌症之診斷及治療方法
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
JP2018049015A (ja) * 2017-09-26 2018-03-29 マイクロ モーション インコーポレイテッド 防炎性の電気フィードスルー
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CA3095198A1 (en) 2018-04-16 2019-10-24 Icahn School Of Medicine At Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021034091A1 (ko) * 2019-08-19 2021-02-25 재단법인 아산사회복지재단 교모세포종의 진단 방법
CA3156803A1 (en) 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
US20240321393A1 (en) * 2021-07-28 2024-09-26 The Regents Of The University Of California Cell-type optimization method and scanner
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
CN113834942B (zh) * 2021-11-02 2024-02-02 河北特温特生物科技发展有限公司 一种胎盘生长因子质控品及其制备方法
CN115840046A (zh) * 2022-08-17 2023-03-24 中国药科大学 一种鉴别anti-VEGF抗体获得性耐药的蛋白聚糖ESM1生物学标记物及其应用
WO2026015087A1 (en) * 2024-07-12 2026-01-15 National University Of Singapore A method for determining a subject's responsiveness to treatment with a vegf inhibitor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001075166A2 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2005236075A1 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
DK2457929T3 (en) 2006-10-04 2016-09-05 Genentech Inc Elisa vegf
AU2008205543A1 (en) 2007-01-18 2008-07-24 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
EP2065399A1 (en) 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
CN101910416A (zh) * 2007-11-09 2010-12-08 健泰科生物技术公司 在癌症患者中诊断性使用的方法和组合物
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
BRPI0918211A2 (pt) 2008-12-23 2015-12-08 Genentech Inc métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
KR101179843B1 (ko) 2009-04-08 2012-09-04 경북대학교 산학협력단 뉴로필린 ２의 위암 진단 및 치료용 용도
AU2010273585B2 (en) 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2464744A1 (en) * 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Biological markers for monitoring patient response to vegf antagonists
AU2010297344A1 (en) * 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
BR112012017084A2 (pt) * 2010-01-12 2016-04-12 Nestec Sa métodos para previsão de resposta de câncer de mama triplo-negativo à terapia
KR101523419B1 (ko) 2010-01-19 2015-05-27 에프. 호프만-라 로슈 아게 베바시주맙 병용 치료법을 위한 종양 조직 기본 바이오마커

Similar Documents

Publication Publication Date Title
JP2015512612A5 (https=)
RU2014133164A (ru) Биологические маркеры для идентификации пациентов для лечения антагонистами vegf
Wick et al. Current status and future directions of anti-angiogenic therapy for gliomas
Shen et al. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Sun et al. Treatment of metastatic renal cell carcinoma
Jour et al. Angiogenesis in melanoma: an update with a focus on current targeted therapies
Liebner et al. Thyroid cancer: pathogenesis and targeted therapy
JP2015516806A5 (https=)
Jänne et al. Combined pan-HER and ALK/ROS1/MET Inhibition with dacomitinib and crizotinib in advanced non–small cell lung cancer: results of a phase I study
JP2018508469A5 (https=)
ES2931337T3 (es) Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red
Charville et al. Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine
RU2014143805A (ru) Способы диагностики и композиции для лечения рака
JP2012532628A5 (https=)
RU2012109556A (ru) Биологические маркеры для мониторирования ответа пациента на антагонисты vegf
JP2017523776A5 (https=)
Ordóñez-Morán et al. Complex metastatic niches: already a target for therapy?
Bagnasco et al. Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors
Cassinello et al. Role of taxanes in advanced prostate cancer
Harari et al. Sirolimus therapy for patients with lymphangioleiomyomatosis leads to loss of chylous ascites and circulating LAM cells
Méndez-Vidal et al. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Rajhbeharrysingh et al. Medical therapy for advanced forms of thyroid cancer
WO2018015522A1 (en) Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation
JP2014168434A (ja) 肺癌患者の治療の有効性の予測検査方法及び肺癌治療剤のスクリーニング方法
Steendam et al. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma